Introduction
The prevalence of central sleep apnoea (CSA) in patients with heart failure (HF) is 25-40%, 1 with rates increasing in parallel with HF severity. 2 In addition, the presence of CSA in patients with HF is a marker of worse prognosis. 3 -5 Adaptive servo-ventilation (ASV) is a type of positive airway pressure that is particularly effective in ameliorating CSA. 6 Some smaller studies, not all randomised, confirmed by later meta-analysis, have reported an improvement in left ventricular ejection fraction (LVEF) in patients with HF being treated with ASV. 7 -10 ASV has also been shown to improve levels of the biomarker B-type natriuretic peptide (BNP) 6, 11, 12 and functional status 8 in HF patients with central apnoea. The SERVE-HF (Treatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnoea by Adaptive Servo-Ventilation in Patients With Heart Failure) trial investigated the effects of adding ASV to guideline-based medical management on survival and cardiovascular outcomes in patients with HF with reduced ejection fraction (HFrEF) and predominant CSA. 13 The study did not show a difference between the ASV and control groups for the primary endpoint -a composite of time to first event of death from any cause, life-saving cardiovascular intervention (transplantation, implantation of a long-term ventricular assist device, resuscitation after sudden cardiac arrest, or appropriate life-saving shock) or unplanned hospitalisation for worsening HF -but there was a statistically and clinically significant increased risk of all-cause, and cardiovascular, mortality in the ASV vs. control group.
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On the basis of existing data, 7 -10 including a meta-analysis, 14 it was felt that the most likely mechanism of benefit of ASV in patients with HF would be improvements in left ventricular geometry. Therefore, SERVE-HF was designed to include a major substudy (NCT01164592), 15 with the aim of providing insight into mechanistic changes underlying outcome data for a subset of study participants; the primary endpoint was change in LVEF from baseline to 12 months. This paper reports cardiac function and biomarker results from the SERVE-HF substudy.
Methods

Study population
Of 91 centres participating in SERVE-HF, 29 contributed patients to the major substudy. Participants in the substudy were a subgroup of those enrolled in the SERVE-HF trial. Inclusion and exclusion criteria have been reported in detail previously. 13, 15 Briefly, patients were aged ≥22 years and had symptomatic chronic HF [New York Heart Association (NYHA) class III or IV, or class II with ≥1 HF-related hospitalisation in the previous 24 months] and reduced LVEF (≤45%). All were receiving stable, guideline-based medical treatment for HF. With respect to sleep-disordered breathing, subjects had predominant CSA defined as an apnoea-hypopnoea index (AHI) of ≥15/h, with >50% central events and a central AHI of ≥10/h, derived from full polysomnography (based on total sleep time), documented <4 weeks before randomisation, with flow measurements performed with a nasal cannula. Additional exclusion criteria were amyloidosis, hypertrophic cardiomyopathy or arteriovenous fistulas, and diuretic dosage more than doubled within the 4 weeks prior to randomisation. 
Study intervention
SERVE-HF participants were randomised to receive optimal medical therapy 16 for HF alone, or in combination with ASV (Auto Set CS, ResMed). Full details of ASV titration and settings have been reported previously.
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Assessments and follow-up
Substudy evaluations were performed at baseline, and at 3 and 12 months after randomisation. These included echocardiography and serial cardiac magnetic resonance imaging (cMRI) to determine left ventricular volumes, mass and ejection fraction. 15 The substudy was completed when all 312 patients had been followed for 12 months.
Echocardiography and cMRI were performed ≥3 h after the end of ASV therapy according to standardised protocols using equipment that . met predefined technical specifications; analysis was performed centrally by a core laboratory. LVEF was determined from a four-chamber view using the modified biplane Simpson method. Blood was drawn at substudy visits, centrifuged locally and stored locally at −20 ∘ C or below, and then shipped under refrigeration to the core laboratory where samples were stored at −80 ∘ C until biomarker analyses were performed.
Study outcomes
The primary endpoint of the substudy was the change in echocardiographically determined LVEF from baseline to 12 months. Secondary endpoints included changes in left and right ventricular function, left ventricular systolic and diastolic indexed volumes, left and right ventricular mass, left ventricular sphericity index, left ventricular end-systolic global wall stress, and biomarker levels [N-terminal pro BNP (NT-proBNP), soluble growth stimulation expressed gene 2 (sST2), interleukin-1 receptor-like 1, galectin-3, high-sensitivity troponin T and troponin I, neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, creatinine, high sensitivity C-reactive protein (hs-CRP), tumour necrosis factor-(TNF-), ferritin, and leptin]. These biomarkers were included to provide information about the HF syndrome, renal function and systemic inflammation.
Sample size
The primary endpoint was the difference in ventricular remodelling between the ASV and control groups from baseline to 12 months, as determined by echocardiographic measurement of LVEF. Assuming that a 4% improvement in LVEF is clinically meaningful, with a residual standard deviation (SD) of measurement of 11.5% determined based on published data, 17 with = 0.05 and 1 − = 0.80, it was calculated that a total sample size of 240 evaluable patients would be required. With a conservative estimated drop-out rate of about 20%, the target sample size was 300 patients.
Statistical analyses
Analysis of the primary endpoint was performed using analysis of covariance (ANCOVA) with study group as the only factor and baseline LVEF as the only covariate. The study hypothesis was tested using the two-sided parameter coefficient t-test of the intervention group with a two-sided = 0.05. The primary analysis was performed in the intention-to-treat population, consisting of all substudy patients. Missing LVEF values (baseline and 12 months) were imputed. For the primary analysis, a multiple imputation procedure (20 repetitions) was performed in the pooled data set using baseline patient characteristics. Alternative imputation methods (multiple imputations only for 12-month value, last observation carried forward, expectation-maximisation and hot deck imputation) were also used in the analysis of the sensitivity of the results from assumptions. For analyses of changes in the secondary endpoints at 12 months, the ANCOVA model of the primary analysis was used analogously. Because we did not impute missing values for secondary outcomes, only data for patients with baseline and 12-month values (variable-wise complete cases) were evaluated. Where appropriate, continuous outcomes were log-transformed before analysis. Mixed models with random intercept for patient and allowing for first order autoregression were used to visualise differences between groups over the course of the study ( 
Results
Patients
SERVE-HF centres in Germany (recruiting 246 patients), France (16 patients), Finland (7 patients), UK (3 patients), Australia (29 patients), Czech Republic (7 patients), Switzerland (3 patients) and the Netherlands (1 patient) contributed patients to the substudy (total n = 312). Table 1 details baseline demographics and characteristics for substudy patients. There were no significant differences in baseline characteristics between the control and ASV groups ( Table 1) . The number of patients who had data available for analysis varied for each parameter (range 23-249) (Figure 1) . The baseline demographic, clinical characteristics and endpoint event rates of patients who did, or did not, participate in the substudy are shown in the supplementary material online, Tables S1 and S2.
Echocardiography
A small increase in LVEF over the study period was seen in both treatment groups ( Table 2 ). The primary endpoint parameter, change in LVEF from baseline to 12 months, did not differ significantly (P = 0.222) between the ASV and control groups ( Table 2 and supplementary material online, Figure S1 ). This result was robust when different imputation methods were used ( Table 2 ). In addition, there were no significant differences between the two groups with respect to changes in left ventricular dimensions, wall thickness or measures of diastolic function or right ventricular dimensions and tricuspid annular plane systolic excursion (TAPSE) over the 12-month follow-up period ( Table 3 ). The adjusted analysis also did not show any significant between-group differences. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Cardiac magnetic resonance imaging
cMRI was only feasible in a small subset of substudy patients due to the frailty of the population and the high number of implanted devices (n = 12-21 in the control group and n = 11-21 in the ASV group for each cMRI parameter). However, these data were consistent with echocardiographic findings, and showed no significant differences between the ASV and control groups in change from baseline to 12 months for any cMRI parameters assessed.
Biomarkers
Reduction in plasma NT-proBNP concentration was seen in both the ASV and control groups, with no significant between-group difference at 12 months (Table 4 and supplementary material online, Figure S2 ). There were no significant differences between treatment groups in changes in troponin T, troponin I, sST2, galectin-3, cystatin C, creatinine, NGAL, hs-CRP and TNF-( Table 4 ). There were also no significant between-group differences in the adjusted analysis. . 
Discussion
In this analysis of SERVE-HF major substudy data, there were no statistically significant differences between the ASV and control groups with respect to changes in echocardiographically and cMRI-determined cardiac structure or function, or a wide variety of cardiac, renal and systemic biomarkers. Although there were improvements in some of the parameters assessed during ASV therapy (e.g. LVEF and NT-proBNP), similar improvements also occurred in the control group, i.e. none of the between-group differences reached statistical significance. These findings suggest that the treatment of predominant CSA in HFrEF with ASV therapy did not meaningfully change cardiac structure or function, or biomarkers of heart function, renal function, or systemic inflammation. This is in keeping with the lack of effect of ASV on both general and disease-specific quality of life in the main SERVE-HF study, along with a lack of difference in HF-related hospitalisations between the ASV and control groups. 13 The substudy findings are also in alignment with the results of multistate modelling analysis, which did not show any increase in HF hospitalisations and suggested that the mortality risk in SERVE-HF patients allocated to ASV is most apparent for cardiovascular death without preceding hospitalisation and therefore likely sudden (cardiac) death.
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The SAVIOR-R trial is another randomised clinical trial (RCT), albeit smaller and shorter in duration, of ASV in patients with HFrEF receiving guideline-based medical therapy, irrespective of the presence or severity of sleep-disordered breathing. 19 As was the case in the major substudy of SERVE-HF, SAVIOR-R showed that LVEF improved from baseline in both the ASV and control groups, with no significant between-group differences. There were also no significant differences between the ASV and control groups in the change from baseline in all echocardiographic parameters and in plasma NT-proBNP concentration, consistent with our results. Also consistent with the main SERVE-HF study was a lack of significant difference between ASV and control with respect to disease-specific quality of life, although SAVIOR-R reported a significantly greater improvement in NYHA class in the ASV vs. Although ASV did not improve left ventricular structure and function in HFrEF patients enrolled in the SERVE-HF study, these parameters have been modified by other forms of treatment for patients with HF. Compared with conventional therapy, use of cardiac resynchronisation therapy (CRT) has been associated with significant improvements in LVEF, and left ventricular end-diastolic and end-systolic volumes in patients with mild-to-moderate 20 -22 or moderate-to-severe 23, 24 HF. In terms of guideline-based optimal HF therapy, both angiotensin-converting enzyme inhibitors and beta-blockers have been shown to improve left ventricular function. 25, 26 Beneficial effects on biomarkers have also been documented after successful CRT 27 and in patients receiving medical HF therapies. 28 SERVE-HF showed an increase in all-cause and cardiovascular mortality explained by an increase in sudden (presumed cardiac) death. There are no reliable biomarkers of sudden cardiac death risk. Our data suggest that the increased risk of cardiovascular mortality is not explained by adverse remodelling or worsening of the HF syndrome as assessed from the perspectives of NT-proBNP, renal function and systemic inflammation.
The lack of effect of ASV on LVEF in RCTs including HF patients with CSA is in contrast to positive effects of positive airway pressure therapy on left ventricular function that have been reported in patients with HF and obstructive sleep apnoea. Treatment with continuous positive airway pressure was associated with significant improvements in LVEF and quality of life vs. control over one month in a randomised controlled study of 24 patients, 29 and significantly improved LVEF and significantly decreased heart rate, systolic blood pressure and the left ventricular end-systolic dimension over 3 months in another randomised study of 55 patients. 30 These data are from a substudy of a larger trial, but the study protocol was prespecified and analyses were conducted prospectively. The substudy was only powered to detect changes in LVEF. The fact that only a subset of SERVE-HF patients participated in the major substudy meant that the sample size was smaller, particularly for some subgroup analyses.
In conclusion, the SERVE-HF substudy did not observe any statistically significant effect of ASV, either positive or negative, on cardiac structure and function or on cardiac biomarkers, renal function and systemic inflammation over a 12-month period in patients with HFrEF and CSA. These findings indicate that the increased cardiovascular mortality reported in the main SERVE-HF study may not be related to adverse remodelling or worsening of the HF syndrome. While in keeping with the lack of change in HF hospitalisations reported in the parent study, these findings do not explain the increased risk of sudden (presumably cardiac) death, a question that needs to be investigated in larger prospective randomised studies.
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